Company Overview and News


Add CELG
to your dashboard

Headline News

UPDATE 1-J&J multiple myeloma drug succeeds in first-line combination study

5h reuters
(Reuters) - Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday. (56-0)

Juno Clinical Trial Updates Continue To Impress

6h seekingalpha
Lead candidate JCAR017, in collaboration and license deal with Celgene, is demonstrating impressive efficacy and safety in early DLCBL trials. (78-1)

J&J multiple myeloma drug succeeds in first-line combination study

8h in.reuters
(Reuters) - Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday. (56-0)

Options Writing Has Been Very Profitable For 2017!

15h seekingalpha
Greetings, all. As we enter into the final few weeks of 2017, I thought it would be opportune to summarize progress across the board. I will deal with my option writing this week. (184-0)

Celgene Corporation Stock Is a Steal Right Now, Here’s Why

19h investorplace
A number of biotech firms that have real long-term growth have for some reason, cheaper share prices than you’d expect, and Celgene Corporation (NASDAQ:CELG) could be one of the biggest bargains of all. (56-0)

Celgene (CELG) a Sell on Flagging Quant Score

19h investorplace
The current recommendation of Sell for Celgene Corp (NASDAQ:CELG) has been derived by using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for the last month. (56-0)

Agios Posts New Data on Glioma Candidate from Dose Expansion

2017-11-20 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced new data from the dose expansion part of a phase I study, evaluating its IDH1 mutant inhibitor, ivosidenib (AG-120), as a single agent for treating low grade isocitrate dehydrogenase-1 mutant (IDH1m) glioma. Data was presented at the annual meeting of the Society for Neuro-Oncology (“SNO”) in San Francisco. (115-0)

Victory Formation Long/Short Portfolio Update - November 2017

2017-11-20 seekingalpha
I have made some changes this week to my long/short portfolio example listed on Wall Street Survivor. I have basically reduced the long S&P 500 ETF exposure in exchange for some regular individual company longs, covered a few shorts in favor of better scoring ideas, and traded the long Qualcomm (NASDAQ:QCOM) position for Intel (NASDAQ:INTC) and Cisco (NASDAQ:CSCO) shares. The net-long posture has been reduced closer to net-neutral as a result of the shuffling, after subtracting the precious metals hedge stake. (628-1)

Cancer Space Update: Label Expansion for Three Major Drugs

2017-11-17 zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-1)

CELG Stock: Celgene Corporation Attempts a Breakout | InvestorPlace

2017-11-17 investorplace
Shares of large-cap biotechnology stocks as a group and as represented by the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) rallied on Thursday  as a broader risk-on feel came back to the world of U.S. equities. Among this group, beaten down Celgene Corporation (NASDAQ:CELG) for the first time in more than two months flashed a better-quality trading buy signal. (56-0)

BRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA

2017-11-16 reuters
* Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma (56-0)

Watch Out Gilead, Juno's Strategy Might Just Pay Off

2017-11-16 seekingalpha
Gilead acquired Kite in a blockbuster $11.9 B deal largely for its recently approved CD19 CAR-T product platform. (73-0)

Look At Deutsche International Growth A Fund (SGQAX)

2017-11-16 zacks
Deutsche International Growth A Fund (SGQAX - Free Report) seeks long-term appreciation of capital. SGQAX normally invests in the securities of non-U.S. issuers across the globe, with any market capitalization. SGQAX invests in preferred stocks, convertible securities and warrants. SGQAX also invests about one-fifth of its assets in securities of domestic issuers. (57-0)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-9)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-2)

CUSIP: 151020104